Pd Failed Approaches Autopsy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides detailed information about this mechanism. See the content below for detailed information.
Purpose: Systematic postmortem analysis of failed PD clinical trials to extract lessons and identify what approaches are more likely to succeed.
Each failed trial is scored on five dimensions (0-10 each, max 50 points):
| Dimension | Description |
|---|---|
| Target Validity | Was the biological target sound? |
| Drug Potency | Was the compound sufficiently potent? |
| Brain Delivery | Did the drug reach the target in the brain? |
| Patient Selection | Were patients at the right disease stage? |
| Trial Design | Were endpoints, duration, and power appropriate? |
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 6/10 | JNK pathway implicated in neuronal death, but upstream vs downstream timing unclear |
| Drug Potency | 7/10 | Adequate inhibition in vitro, but exposure in human brain unknown |
| Brain Delivery | 5/10 | Limited BBB penetration data; peripheral vs central activity unclear |
| Patient Selection | 3/10 | Enrolled moderate PD (Hoehn & Yahr 2-3), possibly too advanced |
| Trial Design | 7/10 | 18-month duration may have been insufficient; UPDRS not optimized for neuroprotection |
| Total | 28/50 | — |
Lessons: Early intervention critical; biomarker enrichment needed to identify patients most likely to progress.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 7/10 | Mitochondrial dysfunction is established in PD; CoQ10 supports ETC |
| Drug Potency | 4/10 | doses (300-1200mg) may have been suboptimal; need for higher brain levels |
| Brain Delivery | 3/10 | Poor BBB penetration; requires specialized formulations |
| Patient Selection | 4/10 | Early PD patients but not selected for mitochondrial dysfunction |
| Trial Design | 6/10 | 16-month duration; dose-escalation design may have underpowered |
| Total | 24/50 | — |
Lessons: Standard CoQ10 formulations don't achieve therapeutic brain levels; requires mitoquinone (MitoQ) or specialized delivery.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 6/10 | Energy failure in PD; creatine supports ATP buffering |
| Drug Potency | 6/10 | Adequate dosing (20g load, 5g maintenance) achieved |
| Brain Delivery | 5/10 | Some brain penetration but levels unclear |
| Patient Selection | 4/10 | Early unmedicated PD; may need earlier intervention |
| Trial Design | 5/10 | 5-year LSVT-BIG trial but primary endpoint change sensitive |
| Total | 26/50 | — |
Lessons: Long trials expensive; combination approaches may work better than single agents.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 5/10 | Microglial activation implicated, but minocycline has multiple off-target effects |
| Drug Potency | 5/10 | Antibiotic with anti-inflammatory properties; not optimized for neuroprotection |
| Brain Delivery | 6/10 | Known to cross BBB |
| Patient Selection | 4/10 | Early PD enrolled |
| Trial Design | 6/10 | 12-month duration; N=200 adequate |
| Total | 26/50 | — |
Lessons: Broad-spectrum approaches may have unintended consequences; target specificity matters.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 7/10 | α-Synuclein aggregation is central to PD; antibody approach logical |
| Drug Potency | 7/10 | High-affinity antibody; good target engagement in periphery |
| Brain Delivery | 2/10 | Large mAb cannot cross BBB; peripheral sink may not be sufficient |
| Patient Selection | 5/10 | Early-to-moderate PD; biomarker selection limited |
| Trial Design | 6/10 | Phase 2 design appropriate for signal detection |
| Total | 27/50 | — |
Lessons: BBB penetration is the fundamental challenge for all large-molecule PD therapeutics.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 8/10 | α-Synuclein oligomers targeted; pathophysiologically relevant |
| Drug Potency | 8/10 | High-affinity antibody; good peripheral engagement |
| Brain Delivery | 2/10 | Same BBB issue as all antibodies |
| Patient Selection | 5/10 | Early PD |
| Trial Design | 7/10 | Phase 2 randomized withdrawal design innovative |
| Total | 30/50 | — |
Lessons: Requires BBB disruption technologies (FUS, AAV, intranasal) or Trojan horse approaches.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 8/10 | Neurturin supports dopaminergic neuron survival |
| Drug Potency | 9/10 | AAV-mediated gene transfer achieves sustained expression |
| Brain Delivery | 8/10 | Direct putaminal injection bypasses BBB |
| Patient Selection | 3/10 | Patients with 5+ years disease, likely too advanced for rescue |
| Trial Design | 5/10 | 15-month primary endpoint; long-term follow-up showed benefit |
| Total | 33/50 | — |
Lessons: Gene therapy may work but needs very early intervention; long-term expression beneficial.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 8/10 | AADC converts L-DOPA to dopamine; enzyme activity declines in PD |
| Drug Potency | 9/10 | Gene therapy achieves long-term AADC expression |
| Brain Delivery | 8/10 | Direct putaminal infusion |
| Patient Selection | 4/10 | Advanced patients on high L-DOPA but with response fluctuations |
| Trial Design | 7/10 | Good biomarker (PET) for target engagement |
| Total | 36/50 | — |
Lessons: Best gene therapy outcome; improves L-DOPA responsiveness but not disease modification.
| Dimension | Score | Rationale |
|---|---|---|
| Target Validity | 8/10 | Replace lost dopaminergic neurons |
| Drug Potency | 9/10 | Human fetal cells can integrate and function |
| Brain Delivery | 7/10 | Stereotactic putaminal transplantation |
| Patient Selection | 4/10 | Patients with 10+ years disease; graft may have limited benefit |
| Trial Design | 6/10 | Randomized but small N; long follow-up |
| Total | 34/50 | — |
Lessons: Cell replacement works in principle; timing and immune suppression critical.
BBB Delivery Problem (Average score: 4 - Only 2 of/10)
8 failed approaches had adequate brain delivery
Patient Selection (Average score: 3.6/10)
Target Validity (Average score: 6.9/10)
| Approach | Why It Might Work |
|---|---|
| AAV-GAD (Gad gene therapy) | Direct delivery to STN; proven safety |
| Focused Ultrasound + Antibody | Temporarily opens BBB for drug delivery |
| Intranasal Delivery | Bypasses BBB for peptide/small molecule |
| L地下 Reservoir Implants | Continuous drug delivery to brain |
| Gene Therapy (early) | Before extensive neuron loss |
| Combination Neuroprotection | Multiple targets simultaneously |
The study of Pd Failed Approaches Autopsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page created: 2026-03-05
Cross-links: PD Therapeutic Scorecard, PD Knowledge Gaps, PD Combination Therapy Matrix, Alpha-Synuclein Pathway, Mitochondrial Dysfunction in PD, Gene Therapy for Neurodegenerative Diseases
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 29%